Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Udaya Kompella to Rats, Sprague-Dawley

This is a "connection" page, showing publications Udaya Kompella has written about Rats, Sprague-Dawley.

 
Connection Strength
 
 
 
1.280
 
  1. Patil MA, Kompella UB. Noninvasive Monitoring of Choroid-Retina Autofluorescence and Intravitreal Nanoparticle Disposition in Royal College of Surgeon Rats of Different Ages and Retinal Thinning. J Ocul Pharmacol Ther. 2020 Jul/Aug; 36(6):458-466.
    View in: PubMed
    Score: 0.123
  2. Tyagi P, Barros M, Stansbury JW, Kompella UB. Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab. Mol Pharm. 2013 Aug 05; 10(8):2858-67.
    View in: PubMed
    Score: 0.076
  3. Tyagi P, Kadam RS, Kompella UB. Comparison of suprachoroidal drug delivery with subconjunctival and intravitreal routes using noninvasive fluorophotometry. PLoS One. 2012; 7(10):e48188.
    View in: PubMed
    Score: 0.073
  4. Kadam RS, Bourne DW, Kompella UB. Nano-advantage in enhanced drug delivery with biodegradable nanoparticles: contribution of reduced clearance. Drug Metab Dispos. 2012 Jul; 40(7):1380-8.
    View in: PubMed
    Score: 0.070
  5. Durazo SA, Kadam RS, Drechsel D, Patel M, Kompella UB. Brain mitochondrial drug delivery: influence of drug physicochemical properties. Pharm Res. 2011 Nov; 28(11):2833-47.
    View in: PubMed
    Score: 0.066
  6. Rao VR, Prescott E, Shelke NB, Trivedi R, Thomas P, Struble C, Gadek T, O'Neill CA, Kompella UB. Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR). Invest Ophthalmol Vis Sci. 2010 Oct; 51(10):5198-204.
    View in: PubMed
    Score: 0.061
  7. Sunkara G, Ayalasomayajula SP, DeRuiter J, Kompella UB. Probenecid treatment enhances retinal and brain delivery of N-4-benzoylaminophenylsulfonylglycine: an anionic aldose reductase inhibitor. Brain Res Bull. 2010 Feb 15; 81(2-3):327-32.
    View in: PubMed
    Score: 0.058
  8. Cheruvu NP, Amrite AC, Kompella UB. Effect of diabetes on transscleral delivery of celecoxib. Pharm Res. 2009 Feb; 26(2):404-14.
    View in: PubMed
    Score: 0.055
  9. Amrite AC, Edelhauser HF, Singh SR, Kompella UB. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol Vis. 2008 Jan 29; 14:150-60.
    View in: PubMed
    Score: 0.052
  10. Amrite AC, Edelhauser HF, Kompella UB. Modeling of corneal and retinal pharmacokinetics after periocular drug administration. Invest Ophthalmol Vis Sci. 2008 Jan; 49(1):320-32.
    View in: PubMed
    Score: 0.052
  11. Cheruvu NP, Amrite AC, Kompella UB. Effect of eye pigmentation on transscleral drug delivery. Invest Ophthalmol Vis Sci. 2008 Jan; 49(1):333-41.
    View in: PubMed
    Score: 0.052
  12. Kador PF, Randazzo J, Babb T, Koushik K, Takamura Y, Zhu W, Blessing K, Kompella UB. Topical aldose reductase inhibitor formulations for effective lens drug delivery in a rat model for sugar cataracts. J Ocul Pharmacol Ther. 2007 Apr; 23(2):116-23.
    View in: PubMed
    Score: 0.049
  13. Amrite AC, Ayalasomayajula SP, Cheruvu NP, Kompella UB. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci. 2006 Mar; 47(3):1149-60.
    View in: PubMed
    Score: 0.046
  14. Amrite AC, Kompella UB. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J Pharm Pharmacol. 2005 Dec; 57(12):1555-63.
    View in: PubMed
    Score: 0.045
  15. Ayalasomayajula SP, Kompella UB. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur J Pharmacol. 2005 Mar 28; 511(2-3):191-8.
    View in: PubMed
    Score: 0.043
  16. Ayalasomayajula SP, Kompella UB. Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm Res. 2004 Oct; 21(10):1797-804.
    View in: PubMed
    Score: 0.041
  17. Ayalasomayajula SP, Amrite AC, Kompella UB. Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas. Eur J Pharmacol. 2004 Sep 13; 498(1-3):275-8.
    View in: PubMed
    Score: 0.041
  18. Koushik K, Dhanda DS, Cheruvu NP, Kompella UB. Pulmonary delivery of deslorelin: large-porous PLGA particles and HPbetaCD complexes. Pharm Res. 2004 Jul; 21(7):1119-26.
    View in: PubMed
    Score: 0.041
  19. Sunkara G, Ayalasomayajula SP, Rao CS, Vennerstrom JL, DeRuiter J, Kompella UB. Systemic and ocular pharmacokinetics of N-4-benzoylaminophenylsulfonylglycine (BAPSG), a novel aldose reductase inhibitor. J Pharm Pharmacol. 2004 Mar; 56(3):351-8.
    View in: PubMed
    Score: 0.040
  20. Kompella UB, Bandi N, Ayalasomayajula SP. Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci. 2003 Mar; 44(3):1192-201.
    View in: PubMed
    Score: 0.037
  21. Ayalasomayajula SP, Kompella UB. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur J Pharmacol. 2003 Jan 05; 458(3):283-9.
    View in: PubMed
    Score: 0.037
  22. Aukunuru JV, Sunkara G, Ayalasomayajula SP, DeRuiter J, Clark RC, Kompella UB. A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications. Pharm Res. 2002 Mar; 19(3):278-85.
    View in: PubMed
    Score: 0.035
  23. Raol YH, Joksimovic SM, Sampath D, Matter BA, Lam PM, Kompella UB, Todorovic SM, Gonz?lez MI. The role of KCC2 in hyperexcitability of the neonatal brain. Neurosci Lett. 2020 11 01; 738:135324.
    View in: PubMed
    Score: 0.031
  24. Wang Z, Cheng R, Lee K, Tyagi P, Ding L, Kompella UB, Chen J, Xu X, Ma JX. Nanoparticle-mediated expression of a Wnt pathway inhibitor ameliorates ocular neovascularization. Arterioscler Thromb Vasc Biol. 2015 Apr; 35(4):855-64.
    View in: PubMed
    Score: 0.021
  25. Chowdhury S, Guha R, Trivedi R, Kompella UB, Konar A, Hazra S. Pirfenidone nanoparticles improve corneal wound healing and prevent scarring following alkali burn. PLoS One. 2013; 8(8):e70528.
    View in: PubMed
    Score: 0.019
  26. Vasireddy V, Chavali VR, Joseph VT, Kadam R, Lin JH, Jamison JA, Kompella UB, Reddy GB, Ayyagari R. Rescue of photoreceptor degeneration by curcumin in transgenic rats with P23H rhodopsin mutation. PLoS One. 2011; 6(6):e21193.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)